Home > Insider Trading > Filing (0001447362-20-000068)

Filing Details

Accession Number:: 0001447362-20-000068
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-05-19 16:39:19
Reporting Period:: 2020-05-15

Accepted Time:: 2020-05-19 16:39:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1447362	Castle Biosciences Inc	CSTL	Services-Medical Laboratories (8071)	770701744

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1783205	Iii C. Joseph Cook	C/O Castle Biosciences, Inc. 820 S. Friendswood Drive, Suite 201 Friendswood TX 77546		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-05-15	13,799	$36.39	1,722,137	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2020-05-15	8,117	$37.28	1,714,020	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2020-05-18	5,199	$37.65	1,708,821	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2020-05-18	4,901	$38.40	1,703,920	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2020-05-18	100	$39.00	1,703,820	No	4	S	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	208,053	Direct

Footnotes

The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by MGC Venture Partners 2013, L.P. ("MGC 2013 LP") on March 13, 2020.
This transaction was executed in multiple trades at prices ranging from $36.00 to $36.98, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Held by MGC 2013 LP, MGC Venture Partners 2018, L.P. ("MGC 2018 LP") and MGC Venture Partners QP 2018, L.P. ("MGC 2018 QP LP"). MGC Venture Partners 2013 GP, LLC ("MGC 2013 GP") is the general partner of MGC 2013 LP. MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP LP.
The Reporting Person is a managing director of MGC 2013 GP and a managing partner of MGC 2018 GP, and shares voting and investment power over the shares held by MGC 2013 LP, MGC 2018 LP and MGC 2018 QP LP. The Reporting Person disclaims beneficial ownership of the shares held by MGC 2013 GP, MGC 2018 GP, MGC 2013 LP, MGC 2018 LP and MGC 2018 QP LP as reported herein, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
This transaction was executed in multiple trades at prices ranging from $37.00 to $37.50, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $37.00 to $37.99, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $38.00 to $38.99, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.